Community-based distribution of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy improved coverage but reduced antenatal attendance in southern Malawi.
OBJECTIVE
To evaluate the impact of a 2-year programme for community-based delivery of sulfadoxine-pyrimethamine (SP) on intermittent preventive treatment during pregnancy coverage, antenatal clinic attendance and pregnancy outcome.


METHODS
Fourteen intervention and 12 control villages in the catchment areas of Chikwawa and Ngabu Government Hospitals, southern Malawi, were selected. Village-based community health workers were trained in information, education and counselling on malaria control in pregnancy and the importance of attending antenatal clinics and promoted these messages to pregnant women. In the intervention group community health workers also distributed SP to pregnant women.


RESULTS
In the control area, coverage of intermittent preventive treatment during pregnancy (>2 doses) was low before (44.1%) and during the intervention (46.1%). In the intervention area, coverage increased from 41.5% to 82.9% (P < 0.01). Antenatal clinic attendance (>2 visits) was maintained in control villages at above 90%, but fell in intervention villages from 87.3% to 51.5% (P < 0.01). Post-natal malaria parasitaemia prevalence fell in women from both study areas during the intervention phase (P < 0.05). Increasing the coverage of intermittent preventive treatment during pregnancy to >40% did not significantly improve maternal haemoglobin or reduce low birthweight prevalence.


CONCLUSIONS
Better coverage of community-based intermittent preventive treatment during pregnancy can lower attendance at antenatal clinics; thus its effect on pregnancy outcome and antenatal attendance need to be monitored.
Msyamboza
K P
KP
Malaria Alert Centre, College of Medicine, Blantyre, Malawi.
Savage
E J
EJ
Kazembe
P N
PN
Gies
S
S
Kalanda
G
G
D'Alessandro
U
U
Brabin
B J
BJ
D000293:Adolescent; D000328:Adult; D000740:Anemia / Q000453:epidemiology; D000962:Antimalarials / Q000600:supply & distribution / Q000627:therapeutic use*; D001724:Birth Weight; D003153:Community Health Services / Q000458:organization & administration; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008288:Malaria / Q000453:epidemiology / Q000517:prevention & control*; D008295:Malawi / Q000453:epidemiology; D018512:Parasitemia / Q000453:epidemiology; D010342:Patient Acceptance of Health Care; D011247:Pregnancy; D011295:Prenatal Care / Q000706:statistics & numerical data; D015995:Prevalence; D015397:Program Evaluation; D011739:Pyrimethamine / Q000600:supply & distribution / Q000627:therapeutic use*; D013413:Sulfadoxine / Q000600:supply & distribution / Q000627:therapeutic use*
D000962:Antimalarials; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D011739:Pyrimethamine